English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background  Stereotactic radiosurgery ( SRS ) and stereotactic radiotherapy ( SRT ) are highly conformal, high‐dose radiation treatment techniques used to treat people and dogs with brain tumors.    Objectives  To evaluate the response to  SRS ‐ and  SRT ‐treated tumors using volume and perfusion variables and to measure the survival times of affected dogs.    Animals  Prospective study of 34 dogs with evidence of brain tumors undergoing stereotactic radiosurgery ( SRS ) or stereotactic radiotherapy ( SRT ).    Methods  Computed tomography and  MRI  imaging were used to calculate tumor volume and perfusion at baseline, and at 3 months and 6 months after treatment. Survival analysis was performed to evaluate treatment efficacy.    Results  Mean tumor volume significantly declined from baseline to the first recheck by −0.826 cm 3  (95%  CI : −1.165, −0.487) ( P  < .001); this reduction was maintained at the second recheck. Blood flow and blood volume declined significantly in the tumor after treatment. Median survival was 324 days (95%  CI : 292.8, 419.4), and 4 dogs survived longer than 650 days. Neither actual tumor volume (hazard ratio = 1.21,  P  = .19) nor the change in tumor volume from the baseline (hazard ratio = 1.38,  P  = .12) significantly affected the hazard of death because of the tumor.    Conclusions and Clinical Importance  Stereotactic radiosurgery and  SRT  are effective treatments for reducing tumor volume, blood flow, and blood volume. Treated dogs surviving for more than 1 year are more likely to die from other causes than of their primary brain tumor.  SRS  and  SRT  should be considered for noninvasive treatment of intracranial brain tumors.

Perfusion and Volume Response of Canine Brain Tumors to Stereotactic Radiosurgery and Radiotherapy